Orthogonal assembly of a designed ankyrin repeat protein-cytotoxin conjugate with a clickable serum albumin module for half-life extension

Bioconjugate Chemistry

Volumn 24, Issue 11, 2013, Pages 1955-1966

  Simon, Manuel ^a,b   Frey, Raphael ^a   Zangemeister Wittke, Uwe ^a,b   Plückthun, Andreas ^a  

^a UNIVERSITY OF ZURICH   (Switzerland)

^b UNIVERSITY OF BERN   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACIDS; ASSEMBLY; BODY FLUIDS; CELL ADHESION; COPPER COMPOUNDS; MAMMALS; MOLECULES; TUMORS;

ANKYRIN REPEATS; BINDING PROTEINS; CYTOTOXINS; DRUG-CONJUGATES; HALF LIVES; LIFE EXTENSIONS; MOUSE SERUM; REPEAT PROTEINS; SERUM ALBUMIN; TUMOR-TARGETING;

ANTIBODIES;

AMINO ACID; ANKYRIN; ANTINEOPLASTIC AGENT; BINDING PROTEIN; CUPROUS ION; CYSTEINE; CYTOTOXIN; DESIGNED ANKYRIN REPEAT PROTEIN; EPITHELIAL CELL ADHESION MOLECULE; FC RECEPTOR; MONOMETHYLAURISTATIN F; SERUM ALBUMIN; UNCLASSIFIED DRUG;

ANALYTIC METHOD; ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BINDING AFFINITY; CIRCULATING TUMOR CELL; CONTROLLED STUDY; CYTOTOXICITY; DRUG CONJUGATION; FEMALE; HALF LIFE TIME; MOUSE; NONHUMAN; ORTHOGONAL ROTATION; PHOTOCHEMICAL INTERNALIZATION; PLASMA HALF LIFE; TARGET CELL;

MUS;

ANIMALS; ANKYRIN REPEAT; ANKYRINS; ANTINEOPLASTIC AGENTS; CELL PROLIFERATION; CLICK CHEMISTRY; CYTOTOXINS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SCREENING ASSAYS, ANTITUMOR; HALF-LIFE; HEK293 CELLS; HT29 CELLS; HUMANS; MICE; MODELS, MOLECULAR; MOLECULAR STRUCTURE; OLIGOPEPTIDES; SERUM ALBUMIN; STRUCTURE-ACTIVITY RELATIONSHIP; TUMOR CELLS, CULTURED;

EID: 84888605787     PISSN: 10431802     EISSN: 15204812     Source Type: Journal    
DOI: 10.1021/bc4004102     Document Type: Article

References (43)

1. Adair, J. R., Howard, P. W., Hartley, J. A., Williams, D. G., and Chester, K. A. (2012) Antibody-drug conjugates- A perfect synergy Expert Opin. Biol. Ther. 12, 1191-1206
2. Alley, S. C., Okeley, N. M., and Senter, P. D. (2010) Antibody-drug conjugates: Targeted drug delivery for cancer Curr. Opin. Chem. Biol. 14, 9-9
3. Sapra, P., Hooper, A. T., O'Donnell, C. J., and Gerber, H.-P. (2011) Investigational antibody drug conjugates for solid tumors Expert Opin. Invest. Drug 20, 1131-1149
4. Verma, S., Miles, D., Gianni, L., Krop, I. E., Welslau, M., Baselga, J., Pegram, M., Oh, D.-Y., Diéras, V., Guardino, E., Fang, L., Lu, M. W., Olsen, S., and Blackwell, K. (2012) Trastuzumab emtansine for HER2-positive advanced breast cancer N. Engl. J. Med. 367, 1783-1791
5. Thurber, G. M., Schmidt, M. M., and Wittrup, K. D. (2008) Antibody tumor penetration: Transport opposed by systemic and antigen-mediated clearance Adv. Drug Delivery Rev. 60, 1421-1434
6. Stefan, N., Martin-Killias, P., Wyss-Stoeckle, S., Honegger, A., Zangemeister-Wittke, U., and Plückthun, A. (2011) DARPins recognizing the tumor-associated antigen EpCAM selected by phage and ribosome display and engineered for multivalency J. Mol. Biol. 413, 826-843
7. Boersma, Y. L. and Plückthun, A. (2011) DARPins and other repeat protein scaffolds: Advances in engineering and applications Curr. Opin. Biotechnol. 22, 849-857
8. Binz, H. K., Amstutz, P., and Plückthun, A. (2005) Engineering novel binding proteins from nonimmunoglobulin domains Nat. Biotechnol. 23, 1257-1268
9. Interlandi, G., Wetzel, S. K., Settanni, G., Plückthun, A., and Caflisch, A. (2008) Characterization and further stabilization of designed ankyrin repeat proteins by combining molecular dynamics simulations and experiments J. Mol. Biol. 375, 837-854
10. Zahnd, C., Kawe, M., Stumpp, M. T., de Pasquale, C., Tamaskovic, R., Nagy-Davidescu, G., Dreier, B., Schibli, R., Binz, H. K., Waibel, R., and Plückthun, A. (2010) Efficient tumor targeting with high-affinity designed ankyrin repeat proteins: Effects of affinity and molecular size Cancer Res. 70, 1595-1605
11. Steiner, D., Forrer, P., and Plückthun, A. (2008) Efficient selection of DARPins with sub-nanomolar affinities using SRP phage display J. Mol. Biol. 382, 1211-1227
12. Zahnd, C., Pecorari, F., Straumann, N., Wyler, E., and Plückthun, A. (2006) Selection and characterization of Her2-binding designed ankyrin repeat proteins J. Biol. Chem. 281, 35167-35175
13. Martin-Killias, P., Stefan, N., Rothschild, S., Plückthun, A., and Zangemeister-Wittke, U. (2011) A novel fusion toxin derived from an EpCAM-specific designed ankyrin repeat protein has potent antitumor activity Clin. Cancer Res. 17, 100-110
14. Simon, M., Stefan, N., Plückthun, A., and Zangemeister-Wittke, U. (2013) Epithelial cell adhesion molecule-targeted drug delivery for cancer therapy Expert Opin. Drug Delivery 10, 451-468
15. Dreier, B., Honegger, A., Hess, C., Nagy-Davidescu, G., Mittl, P. R. E. P., Grütter, M. G., Belousova, N., Mikheeva, G., Krasnykh, V., and Plückthun, A. (2013) Development of a generic adenovirus delivery system based on structure-guided design of bispecific trimeric DARPin adapters Proc. Natl. Acad. Sci. U.S.A. 110, E869-E877
16. Winkler, J., Martin-Killias, P., Plückthun, A., and Zangemeister-Wittke, U. (2009) EpCAM-targeted delivery of nanocomplexed siRNA to tumor cells with designed ankyrin repeat proteins Mol. Cancer Ther. 8, 2674-2683
17. Simon, M., Zangemeister-Wittke, U., and Plückthun, A. (2012) Facile double-functionalization of designed ankyrin repeat proteins using click and thiol chemistries Bioconjugate Chem. 23, 279-286
18. Tamaskovic, R., Simon, M., Stefan, N., Schwill, M., and Plückthun, A. (2011) Designed ankyrin repeat proteins (DARPins) from research to therapy Methods Enzymol. 503, 101-134
19. Schmidt, M. M. and Wittrup, K. D. (2009) A modeling analysis of the effects of molecular size and binding affinity on tumor targeting Mol. Cancer Ther. 8, 2861-2871
20. Veronese, F. M. and Pasut, G. (2005) PEGylation, successful approach to drug delivery Drug Discovery Today 10, 1451-1458
21. Bailon, P. and Won, C.-Y. (2009) PEG-modified biopharmaceuticals Expert Opin. Drug Delivery 6, 1-16
22. Angelini, A., Diderich, P., Morales-Sanfrutos, J., Thurnheer, S., Hacker, D., Menin, L., and Heinis, C. (2012) Chemical macrocyclization of peptides fused to antibody Fc fragments Bioconjugate Chem. 23, 1856-1863
23. Kontermann, R. E. (2011) Strategies for extended serum half-life of protein therapeutics Curr. Opin. Biotechnol. 22, 868-876
24. Smith, B. J., Popplewell, A., Athwal, D., Chapman, A. P., Heywood, S., West, S. M., Carrington, B., Nesbitt, A., Lawson, A. D. G., Antoniw, P., Eddelston, A., and Suitters, A. (2001) Prolonged in vivo residence times of antibody fragments associated with albumin Bioconjugate Chem. 12, 750-756
25. Dennis, M. S., Zhang, M., Meng, Y. G., Kadkhodayan, M., Kirchhofer, D., Combs, D., and Damico, L. A. (2002) Albumin binding as a general strategy for improving the pharmacokinetics of proteins J. Biochem. 277, 35035-35043
26. Holt, L. J., Basran, A., Jones, K., Chorlton, J., Jespers, L. S., Brewis, N. D., and Tomlinson, I. M. (2008) Anti-serum albumin domain antibodies for extending the half-lives of short lived drugs Protein Eng. Des. Sel. 21, 283-288
27. Nguyen, A., Reyes, A. E., Zhang, M., McDonald, P., Wong, W. L. T., Damico, L. A., and Dennis, M. S. (2006) The pharmacokinetics of an albumin-binding Fab (AB.Fab) can be modulated as a function of affinity for albumin Protein Eng. Des. Sel. 19, 291-297
28. Elsadek, B. and Kratz, F. (2012) Impact of albumin on drug delivery-New applications on the horizon J. Controlled Release 157, 4-28
29. Schnitzer, J. E. J. and Oh, P. P. (1992) Antibodies to SPARC inhibit albumin binding to SPARC, gp60, and microvascular endothelium Am. J. Physiol. 263, H1872-H1879
30. Di Costanzo, F., Gasperoni, S., Rotella, V., and Di Costanzo, F. (2009) Targeted delivery of albumin bound paclitaxel in the treatment of advanced breast cancer Oncotargets Ther. 2, 179-188
31. Simon, M., Stefan, N., Borsig, L., Plückthun, A., and Zangemeister-Wittke, U. (2013) Increasing the anti-tumor effect of an EpCAM-targeting fusion toxin by facile click PEGylation. Mol. Cancer Ther., in press.
32. Chang, P. V., Prescher, J. A., Sletten, E. M., Baskin, J. M., Miller, I. A., Agard, N. J., Lo, A., and Bertozzi, C. R. (2010) Copper-free click chemistry in living animals Proc. Natl. Acad. Sci. U.S.A. 107, 1821-1826
33. Chaudhury, C., Brooks, C. L., Carter, D. C., Robinson, J. M., and Anderson, C. L. (2006) Albumin binding to FcRn: Distinct from the FcRn-IgG interaction Biochemistry 45, 4983-4990
34. Doronina, S. O., Mendelsohn, B. A., Bovee, T. D., Cerveny, C. G., Alley, S. C., Meyer, D. L., Oflazoglu, E., Toki, B. E., Sanderson, R. J., Zabinski, R. F., Wahl, A. F., and Senter, P. D. (2006) Enhanced activity of monomethylauristatin F through monoclonal antibody delivery: Effects of linker technology on efficacy and toxicity Bioconjugate Chem. 17, 114-124
35. Andersen, J. T., Bekele Daba, M., Berntzen, G., Michaelsen, T. E., and Sandlie, I. (2010) Cross-species binding analyses of mouse and human neonatal Fc receptor show dramatic differences in immunoglobulin G and albumin binding J. Biol. Chem. 285, 4826
36. Andersen, J. T., Dalhus, B., Cameron, J., Daba, M. B., Plumridge, A., Evans, L., Brennan, S. O., Gunnarsen, K. S., BjøraÌŠs, M., and Sleep, D. (2012) Structure-based mutagenesis reveals the albumin-binding site of the neonatal Fc receptor Nat. Commun. 3, 610
37. Kratz, F. (2008) Albumin as a drug carrier: Design of prodrugs, drug conjugates and nanoparticles J. Controlled Release 132, 13-13
38. Thibaudeau, K., Leger, R., Huang, X., Robitaille, M., Quraishi, O., Soucy, C., Bousquet-Gagnon, N., van Wyk, P., Paradis, V., Castaigne, J., and Bridon, D. (2005) Synthesis and evaluation of insulin-human serum albumin conjugates Bioconjugate Chem. 16, 1000-1008
39. Kratz, F., Warnecke, A., Scheuermann, K., Stockmar, C., Schwab, J., Lazar, P., Drückes, P., Esser, N., Drevs, J., Rognan, D., Bissantz, C., Hinderling, C., Folkers, G., Fichtner, I., and Unger, C. (2002) Probing the cysteine-34 position of endogenous serum albumin with thiol-binding doxorubicin derivatives. Improved efficacy of an acid-sensitive doxorubicin derivative with specific albumin-binding properties compared to that of the parent compound J. Med. Chem. 45, 5523-5533
40. Agard, N. J., Prescher, J. A., and Bertozzi, C. R. (2004) A strain-promoted [3 + 2] azide-alkyne cycloaddition for covalent modification of biomolecules in living systems J. Am. Chem. Soc. 126, 15046-15047
41. Andersen, J. T. and Sandlie, I. (2008) The versatile MHC class I-related FcRn protects IgG and albumin from degradation: Implications for development of new diagnostics and therapeutics Drug Metab. Pharmacokinet. 24, 318-332
42. Conte, M. L., Staderini, S., Marra, A., Sanchez-Navarro, M., Davis, B. G., and Dondoni, A. (2011) Multi-molecule reaction of serum albumin can occur through thiol-yne coupling Chem. Commun. 47, 11086-11088
43. van Geel, R., Pruijn, G. J. M., van Delft, F. L., and Boelens, W. C. (2012) Preventing thiol-yne addition improves the specificity of strain-promoted azide-alkyne cycloaddition Bioconjugate Chem. 23, 392-398